Promising new compound for treating stroke
Researchers at the University of Copenhagen have designed, produced and patented a new chemical compound for the possible treatment of brain damage caused by stroke. The compound binds 1,000 times more effectively to the target protein in the brain than the potential drug currently being tested on stroke victims. The results of biological tests have just been published in the renowned journal PNAS.
More than 140,000 people die each year from stroke in the United States. Stroke causes the brain to release large amounts of glutamate, an activating signal compound, all at once. This overactivates the receptors in the surrounding healthy tissue, causing the level of calcium in the cells to rise dramatically. This then kick-starts a toxic chain reaction causing cell death. Scientists believe that this process is the cause of the brain damage that occurs in the wake of a stroke. Therefore they are looking for compounds that can limit cell death:
"Research on animal models shows that the new compound we have designed and produced reduces the dead area in the brain after a stroke by 40 per cent. In addition, we can show that our compound is far more biologically effective than the potential drug currently being tested in clinical trials," explains Anders Bach, medicinal chemist and postdoc at the Faculty of Health and Medical Sciences.
Improving motor function in animals
A research project based at the Faculty of Health and Medical Sciences is the catalyst for the development of drugs to treat brain damage resulting from stroke. A new chemical compound has shown to be extremely potent, binding 1,000 times better than the potential drug currently under clinical development. Biological tests also indicate that the new compound shows high biological activity in animal models and is able to pass through the nearly impermeable blood-brain barrier, which is otherwise a fundamental challenge in clinical drug development. The results have just been published in the scientific journal PNAS Proceedings of the National Academy of Sciences.
"Our compound is able to pass through the blood-brain barrier, but also interesting is that it improves motor function in the animals that have been subject to stroke, for example, seen as increased grip strength in the paws of the mice," relates Anders Bach.
Alternative angle to drug development
Previously the development of drugs to combat brain damage resulting from stroke focused on blocking the receptors for signal compounds in the brain, such as glutamate. While this protected the receptor against the danger of overactivation, it unfortunately also influenced the normal vital functions of the receptor, causing unacceptable side effects.
Therefore in recent years there has been increased interest in an alternative strategy where the drug does not influence the receptor directly, but instead acts on the interactions between the receptor and the proteins in the cell. This is an important area of focus for the Chemical Biology research team at the University of Copenhagen:
"Our research is concentrated on disrupting the interaction between the so-called NMDA receptor and the intracellular protein PSD-95. Other scientists have shown interest in the same area one group has developed a particularly interesting compound that is currently undergoing clinical development. However, we have reconsidered the design of the compounds in this area and come up with a new one that is more effective," states Anders Bach.
Detailed understanding of the molecular mechanism
In order to find compounds that can detach the PSD-95 protein from the NMDA receptor, one must have a method for measuring the extent to which the compounds bind to PSD-95.
"We have established a method fluorescence polarisation that has been very successful in helping us develop a number of potent compounds over a long period of time," recounts Anders Bach. He adds that scientists have committed many resources to finding out exactly how the compounds bind to PSD-95 using for example sophisticated biophysical methods. This has resulted in detailed understanding of the molecular mechanisms that cause the high level of activity.
Anders Bach hopes that the new compound can form the basis for a new drug on the global market, but he emphasises that such a process is long and complicated:
"Although we are very satisfied with the new results in terms of the possible treatment of brain damage due to stroke, many things can go wrong in the long drug development process. So even though the compound binds effectively in laboratory studies and shows promising biological activity in animal models, we will still have many challenges to overcome," concludes Anders Bach.
The PSD-95 protein is also involved in chronic pain as well as Alzheimer 's disease so the new compound may also prove interesting to examine in connection with other conditions.
Journal reference: Proceedings of the National Academy of Sciences
Provided by University of Copenhagen
- Stroke's 'death signal' discovered; may aid drug development Jan 21, 2010 | not rated yet | 0
- Neuroscientist says a critical protein prevents secondary damage after stroke Nov 02, 2011 | not rated yet | 0
- Biologists reveal novel drug binding site in NMDA receptor subunit Jun 16, 2011 | not rated yet | 0
- New understanding about mechanism for cell death after stroke leads to possible therapy Nov 22, 2009 | not rated yet | 0
- New drug target for Alzheimer's, stroke discovered Oct 11, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be a term called "intestinal metaplasia" of stomach
16 hours ago Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
- More from Physics Forums - Medical Sciences
More news stories
Trends in Helicobacter pylori (H. pylori) and smoking explain a significant proportion of the decline of intestinal-type noncardia gastric adenocarcinoma (NCGA) incidence in US men between 1978 and 2008, and are estimated ...
Medical research 6 hours ago | not rated yet | 0
Widely available in pharmacies and health stores, phosphatidylserine is a natural food supplement produced from beef, oysters, and soy. Proven to improve cognition and slow memory loss, it's a popular treatment for older ...
Medical research 10 hours ago | 5 / 5 (1) | 0 |
Researchers at Emory University have identified a protein that stimulates a pair of "orphan receptors" found in the brain, solving a long-standing biological puzzle and possibly leading to future treatments for neurological ...
Medical research 11 hours ago | not rated yet | 0 |
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
Medical research 11 hours ago | 4.4 / 5 (5) | 0 |
Researchers at the University of Illinois at Chicago College of Medicine will study gender differences in how the heart uses and stores fat—its main energy source—and how changes in fat metabolism play ...
Medical research 14 hours ago | not rated yet | 0
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
11 hours ago | 4.2 / 5 (5) | 0 |
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
9 hours ago | 4.9 / 5 (9) | 0 |
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
5 hours ago | 3 / 5 (2) | 0
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
6 hours ago | 5 / 5 (3) | 0 |
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
7 hours ago | not rated yet | 0 |
Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.
8 hours ago | 5 / 5 (3) | 0 |